Drugs in Focus: Octreotide Use in Children With Gastrointestinal Disorders

Emmanuel Mas1, Osvaldo Borrelli2, Ilse Broekaert3

  • 1Unité de Gastroentérologie, Hépatologie, Nutrition, Diabétologie et Maladies Héréditaires du Métabolisme, Hôpital des Enfants, CHU de Toulouse; IRSD, Université de Toulouse, INSERM, INRAE, ENVT, UPS, Toulouse, France.

Insights

Octreotide, a somatostatin analogue, is widely used in children for various gastrointestinal conditions. This review examines the evidence for its efficacy and safety in pediatric patients, highlighting a need for more randomized clinical trials.

Area of Science:

  • Pediatric Gastroenterology
  • Clinical Pharmacology

Background:

  • Octreotide, a somatostatin analogue, has a long history of use in pediatric gastrointestinal disorders.
  • Established uses include treating bleeding, chylothorax/ascites, lymphangiectasia, pancreatitis, dysmotility, and severe diarrhea.
  • A significant gap exists in high-level evidence, specifically randomized clinical trials (RCTs), for its pediatric application.

Purpose of the Study:

  • To conduct a literature review to assess the existing evidence on the efficacy and safety of octreotide in children.
  • To identify the scope of current research and clinical application of octreotide in pediatric gastrointestinal conditions.

Main Methods:

  • A systematic literature search was performed using PubMed.
  • The search covered the period from 2000 to 2021.
  • Keywords included "octreotide," "children," and specific gastrointestinal conditions such as "bleeding," "chylous ascites," "chylothorax," "acute pancreatitis," "lymphangiectasia," "diarrhea," and "intestinal dysmotility."

Main Results:

  • The review synthesizes available data on octreotide's use in pediatric gastrointestinal conditions.
  • Evidence regarding efficacy and safety profiles across various indications is evaluated.
  • The scarcity of randomized controlled trials is a key finding.

Conclusions:

  • Octreotide is frequently utilized in pediatric practice for a range of gastrointestinal issues.
  • Further high-quality research, particularly randomized clinical trials, is necessary to definitively establish the efficacy and safety of octreotide in children.
  • Current evidence is largely based on observational data and case reports.

Related Concept Videos

Drugs for Peptic Ulcer Disease: Sucralfate as Mucosal Protective Agents01:24

Drugs for Peptic Ulcer Disease: Sucralfate as Mucosal Protective Agents

In the intricate landscape of the gastric lumen, excessive acid secretion disrupts the natural defense mechanisms, weakening the mucus-bicarbonate barrier. This vulnerability allows pepsin to infiltrate epithelial cells, digesting mucosal proteins and triggering erosion, leading to ulcer formation.
In this scenario, mucosal protective agents like sucralfate play an essential role. Sucralfate, a complex of sulfated sucrose and aluminum hydroxide, demonstrates its usefulness in acidic conditions,...
Drugs for Peptic Ulcer Disease: Prostaglandin Analogs as Mucosal Protective Agents01:20

Drugs for Peptic Ulcer Disease: Prostaglandin Analogs as Mucosal Protective Agents

The gastric mucosa produces prostaglandins E2 (PGE2) and prostacyclin (PGI2), crucial in maintaining gastric health. They exert cytoprotective effects, including increasing bicarbonate secretion, releasing protective mucin, reducing gastric acid output, and preventing harmful vasoconstriction. These effects are mediated through various receptors, such as EP1, EP2, EP3, and EP4.
Non-steroidal anti-inflammatory drugs (NSAIDs) can induce peptic ulcers by inhibiting cyclooxygenase, decreasing...
Drugs Affecting GI Tract Motility: Dopamine Receptor Antagonists01:28

Drugs Affecting GI Tract Motility: Dopamine Receptor Antagonists

Prokinetic agents are specialized medications that stimulate gastrointestinal (GI) motility, promoting food movement through the GI tract. Dopamine, an inhibitory neurotransmitter, plays a significant role in this process, reducing GI motility and indirectly controlling the speed of digestion. Dopamine receptor antagonists, such as metoclopramide and domperidone, offer a unique advantage as prokinetic agents. By blocking the dopamine receptors, these drugs increase GI motility, improving food...
Drugs Affecting GI Tract Motility: Serotonin Receptor Agonists01:23

Drugs Affecting GI Tract Motility: Serotonin Receptor Agonists

Serotonin, a crucial neurotransmitter synthesized by enterochromaffin cells, plays a cardinal role in regulating gastrointestinal (GI) motility. With over 90% of the body's total serotonin in the GI tract, its influence on digestive processes is profound. Serotonin is swiftly released upon various stimuli, such as food boluses or certain drugs, triggering intrinsic sensory neurons in the myenteric plexus and extrinsic vagal and spinal sensory neurons. This leads to the activation of the...